A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Conditions
Corpus Uteri | Larynx | Lung | Soft Tissue | Unknown Sites
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This is a multi-cohort, open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in adult subjects with metastatic solid tumors with elevated Trop-2 expression.
- Trial withImmunomedics, Inc.
- Start Date08/23/2021
- End Date08/31/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Aarti Bhatia, MD, MPH
- Anne Chiang, MD, PhD
- Barbara Burtness, MD
- Elena Ratner, MD, MBA
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- Gary Altwerger, MD
- Hari Deshpande, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Justin Harold, MD
- Kathryn Medow, APRN
- Lynsey Teulings
- Marianne Davies, NP, DNP, MSN, BSN
- Martha Luther
- Masoud Azodi, MD
- Michael Cecchini, MD
- Peter Schwartz, MD
- Roy S. Herbst, MD, PhD
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- Stacey Stein, MD
- Stephanie Cerrito
- Vaagn Andikyan, MD
- Last Updated07/10/2022
- Study HIC#2000025243